ABSTRACT Recently nebulised antibiotics (gentamicin and carbenicillin) have been used successfully to treat respiratory tract infection in patients with cystic fibrosis. No information exists, however, on the choice of nebuliser or the ideal mode of operation with antibiotic solutions, which are often viscous. The aerosol output, droplet size, and nebulisation time were assessed for four common brands of jet nebuliser (Bird, DeVilbiss, Inspiron, and Upmist) used to nebulise 2 ml (80 mg) and 4 ml (160 mg) of gentamicin solution (Garamycin, Kirby-Warrick) at four compressed gas flow rates (6, 8, 10, and 12 l.min-'). There were considerable variations between the nebulisers, DeVilbiss and Upmist being most efficient in the release of respirable (< 5 um diameter) droplets. Droplet size and nebulisation time were inversely proportional to gas flow rate. Aerosol output and nebulisation time were increased by raising the volume fill from 2 to 4 ml, although nebulisation time could still be restricted to 12 minutes or less with DeVilbiss and Upmist at 12 l.min-'. The output of drug in droplets of below 5 um diameter ranged from 7.2 (SE 0.4) to 71.4 (4.3) mg, according to the type of nebuliser, flow rate, and volume fill. These studies suggest that for optimal drug delivery 4 ml gentamicin solution should be nebulised either at a fixed flow rate of 10-12 l.min-' or with a high flow compressor. Previous unsatisfactory clinical results with antibiotic aerosols may have been due in part to incorrect choice of nebuliser or inappropriate operating conditions, or both.
Treatment of chest disorders by inhaled drugs has several potential advantages over use of the oral or intravenous route in that a smaller dose of drug can often be used, there is a low incidence of systemic side effects, and the drug generally begins to act rapidly.' Antibiotics were first given by inhalation in 1946,2 but for many years this form of treatment was considered to have no particular advantage in the treatment of respiratory tract infection.3 Recent studies, however, have shown an improvement in pulmonary function4 and a reduction in the frequency of hospital admission5 in selected patients with cystic fibrosis and Pseudomonas aeruginosa infection when treated regularly with nebulised antibiotics. Aerosol antibiotics offer the prospect of domiciliary treatment over relatively long periods,6 and their use is associated with higher sputum and Address for reprint requests: Dr SP Newman, Department of Thoracic Medicine, Royal Free Hospital, London NW3 2QG.
Accepted 10 April 1985 lower serum concentrations of drug than are achieved with parenteral administration.7
Surprisingly little information exists on the output characteristics of nebulisers, and there is no information at all on the nebulisation of antibiotic solutions, which are more viscous than saline or water.
The present study was carried out to assess the output, droplet size, and nebulisation time of four common brands of jet nebuliser used with a solution of gentamicin at four different compressed gas flow rates, as a basis for guidelines for the most efficient delivery of nebulised antibiotics. 672 recent practice in the treatment of patients with cystic fibrosis with inhaled gentamicin at the Brompton Hospital, London. Nebulisation was performed with four different compressed gas flow rates (6, 8, 10 and 12 1.min-') from an air cylinder. These flows were selected to correspond with the range of flows generated through nebulisers by most electrically driven compressors.
The nebuliser, fitted with mouthpiece, was weighed on a Mettler balance before and after the required solution had been added to the nebuliser reservoir by syringe. Finally, the mass of drug released as aerosol was multiplied by the percentage of the aerosol mass contained in droplets of below 5 ,um diameter to give the mass of gentamicin contained in these droplets.
The data were assumed to be non-normally distributed and were analysed by non-parametric techniques. 8 The Wilcoxon rank sum test for paired data and the Friedman analysis of variance by ranks were used, a p value of S 0.05 being taken to indicate statistical significance.
Results

MASS OF DRUG RELEASED AS AEROSOL
The mass of the initial solution varied from 2.05 to 2.19 g (78.6-84.3 mg gentamicin) for the 2 ml fill and from 4.08 to 4.40 g (156.9-169.2 mg gentamicin) for the 4 ml fill. The mass of solution retained in the nebuliser reservoir ranged from 0.44 to 1.26 g for the 2 ml fill and from 0.52 to 2.28 g for the 4 ml fill. The "dead" mass of the solution underestimated the true "dead" mass of gentamicin retained in the nebuliser because of the increase in concentration of this solution during nebulisation. The ratio of final to initial drug concentration ranged from 1.35 to 1.70 for the 2 ml fill and from 1.45 to 1.96 for the 4 ml fill (table 1) . This ratio did not vary significantly with compressed gas flow rate but was significantly (p < 0.01) higher for the 4 ml fill than for the 2 group.bmj.com on June 26, 2017 -Published by http://thorax.bmj.com/ Downloaded from Evaluation ofjet nebulisers for use with gentamicin solution With the 4 ml fill there was a significant (p < 0.01) negative correlation between nebulisation time and flow rate for the DeVilbiss, Upmist, and Inspiron nebulisers. At 12 l.min-', nebulisation time averaged 9 minutes 50 seconds for Upmist and 12 minutes for DeVilbiss. Nebulisation time increased in proportion to the rise in volume fill from 2 ml to 4 ml.
Discussion
The results show that there is a wide variation in the output of gentamicin aerosol droplets of less than 5 um diameter and in nebulisation time depending on the type of nebuliser used, the volume fill, and the compressed gas flow rate. There was a 10 fold difference between the most and the least efficient delivery systems (means 7.2 mg versus 71.4 mg gentamicin), suggesting that patients might sometimes be underdosed when relatively inefficient systems are used. Previous unsatisfactory clinical results with antibiotic aerosols may have been due in part to the use of relatively poor nebulisers and administration systems, rather than to any inherent failure of the topical antibiotic to work effectively within the bronchial tree.
Our findings confirm that there is a reduction in droplet size with increasing compressed gas flow rate,9 -2 and simultaneously a reduction in nebulisation time.'3 As shown previously, aerosol release is more efficient when the volume fill is increased. '3 These previous studies, however, were performed with other types of nebuliser solution having physical properties different from those of antibiotic solutions (viscosities about 50% higher than that of normal (0.9%) saline-unpublished observations) and their results could not be extrapolated automatically to gentamicin. For instance, with gentamicin, nebulisation times were higher and droplet sizes larger'2 '3 than those observed for normal saline nebulised by Inspiron and Upmist nebulisers at 6 and 8 1.min-'. Variations in the output characteristics of nebulisers according to the physical properties of the drug solution have been predicted on theoretical grounds.'4 '5 Our studies were performed with nebulisers clamped firmly in a fume cupboard with auxiliary air holes closed. While patients do not use nebulisers in precisely this fashion, our concerns were, firstly, to compare the relative merits of different brands of nebuliser, volume fills, and flow rates in an entirely standardised manner and, secondly, to prevent unpleasant antibiotic sprays from being released other than from the mouthpiece.
It is not known whether aerosol antibiotics should be delivered preferentially to the distal or proximal parts of the bronchial tree, and hence the ideal droplet size for these aerosols has yet to be determined precisely. We have therefore assessed nebulisers for their ability to produce " respirable" (< 5 ,um diameter) droplets,9 although some of these droplets will be deposited in the oropharynx and some will be exhaled. Smaller or larger aerosols might be more effective in the treatment of respiratory tract infections, but the most efficient nebulisers (DeVilbiss and Upmist) operating at 10-1 2 1.min-'also optimised the quantities of gentamicin released in droplets of less than 3 When the volume fill was doubled from 2 ml (80 mg) to 4 ml (160 mg), up to 4.3 times more drug was released as aerosol, since a smaller proportion of the drug dose was retained within the nebulisers themselves. A substantial rise in drug output would also be anticipated if 2 ml gentamicin solution was diluted to 4 ml with water or saline. While drug release was more efficient with a 4 ml fill, nebulisation times were doubled and might have become too large for comfortable treatments with some types of nebuliser. With 4 ml solution nebulised at 12 l.min-', however, nebulisation times averaged only 10 and 12 minutes with Upmist and DeVilbiss respectively. Further, these were the times taken to nebulise to "dryness." In practice, treatment mriAght be stopped somewhat earlier (for instance, when nebulisation becomes intermittent), although it is not always possible to detect accurately the point at which this occurs.
In summary, DeVilbiss and Upmist were the most efficient of the brands of nebuliser tested, especially when used to nebulise 4 ml (160 mg) gentamicin solution at 10-12 1.min-'. Several other promising 676 brands of nebuliser are also available. These include models with cylindrical liquid feeds around the air inlet, which are less likely to become blocked by drug residue; and also models with integral valve systems adjacent to the mouthpiece for conducting away exhaled antibiotic via tubing to an exhaust. Studies are now in progress to assess the use of these models with antibiotic solutions.
